Conjugates of hydroxyalkyl starch and a protein are provided herein. The conjugates are formed by a covalent linkage between the hydroxyalkyl starch or a derivative of the hydroxyalkyl starch and the protein. Methods of producing the conjugates and the use of the conjugates also are provided herein.
Conjugates of hydroxyalkyl starch and a protein are provided herein. The conjugates are formed by a covalent linkage between the hydroxyalkyl starch or a derivative of the hydroxyalkyl starch and the protein. Methods of producing the conjugates and the use of the conjugates also are provided herein.
대표청구항▼
1. A conjugate comprising a protein and a polymer derivative, wherein the polymer is a hydroxyalkyl starch (HAS) and the protein is selected from the group consisting of IFN beta, GM-CSF, APC, tPA, A1AT, AT III, factor VII, factor VIII, and factor IX, said conjugate having a structure according to t
1. A conjugate comprising a protein and a polymer derivative, wherein the polymer is a hydroxyalkyl starch (HAS) and the protein is selected from the group consisting of IFN beta, GM-CSF, APC, tPA, A1AT, AT III, factor VII, factor VIII, and factor IX, said conjugate having a structure according to the formula wherein R1, R2 and R3 are independently hydrogen or a hydroxyalkyl group, or hydrogen or a hydroxyethyl group, wherein, in the conjugate, HAS is bonded at its non-oxidized reducing end to a bifunctional linking compound, and the bifunctional linking compound is bonded to an oxidized carbohydrate side chain or an oxidized N-terminal group of the protein,wherein HAS′ is the remaining part of the starch molecule HAS, andwherein L is a substituted or unsubstituted, linear, branched and/or cyclic hydrocarbon residue, optionally comprising at least one heteroatom. 2. The conjugate of claim 1, wherein -L- is —[(CRaRb)mG]n[CRcRd]o— wherein Ra, Rb, Rc, and Rd are independently hydrogen, alkyl, aryl,wherein G is selected from the group consisting of O and S, wherein m is 1, 2, 3 or 4, wherein the residues Ra and Rb may be the same or different in the m groups CRaRb; wherein n is 0 to 20; wherein o is 0 to 20, wherein the residues Rc and Rd may be the same or different in the o groups CRcRd; and wherein n and o are not 0 at the same time. 3. The conjugate of claim 2, wherein Ra, Rb, Rc, and Rd are hydrogen, m is 2, n is 1, and o is 2. 4. The conjugate of claim 1, wherein the hydroxyalkyl starch is hydroxyethyl starch. 5. The conjugate of claim 4, wherein the hydroxyethyl starch has a molecular weight of from 2 to 200 kD. 6. A pharmaceutical composition comprising one or more conjugates of claim 1 and a pharmaceutically acceptable diluent, adjuvant, or carrier, wherein the protein is IFN beta. 7. The conjugate of claim 1, wherein the protein is IFN beta. 8. The conjugate of claim 1, wherein the protein is GM-CSF. 9. The conjugate of claim 1, wherein the protein is APC. 10. The conjugate of claim 1, wherein the protein is tPA. 11. The conjugate of claim 1, wherein the protein is A1AT. 12. The conjugate of claim 1, wherein the protein is AT III. 13. The conjugate of claim 1, wherein the protein is Factor VII. 14. The conjugate of claim 1, wherein the protein is Factor VIII. 15. The conjugate of claim 1, wherein the protein is Factor IX. 16. A pharmaceutical composition comprising the conjugate of claim 1, wherein the protein is GM-CSF. 17. A pharmaceutical composition comprising one or more conjugates of claim 1 and a pharmaceutically acceptable diluent, adjuvant, or carrier, wherein the protein is APC. 18. A pharmaceutical composition comprising one or more conjugates of claim 1 and a pharmaceutically acceptable diluent, adjuvant, or carrier, wherein the protein is tPA. 19. A pharmaceutical composition comprising one or more conjugates of claim 1 and a pharmaceutically acceptable diluent, adjuvant, or carrier, wherein the protein is A1AT. 20. A pharmaceutical composition comprising one or more conjugates of claim 1 and a pharmaceutically acceptable diluent, adjuvant, or carrier, wherein the protein is AT III. 21. A pharmaceutical composition comprising one or more conjugates of claim 1 and a pharmaceutically acceptable diluent, adjuvant, or carrier, wherein the protein is Factor VII. 22. A pharmaceutical composition comprising one or more conjugates of claim 1 and a pharmaceutically acceptable diluent, adjuvant, or carrier, wherein the protein is Factor VIII. 23. A pharmaceutical composition comprising one or more conjugates of claim 1 and a pharmaceutically acceptable diluent, adjuvant, or carrier, wherein the protein is Factor IX. 24. A method comprising administering the conjugate of claim 1 to a human or animal in need thereof, wherein the human or animal is in need of treatment for multiple sclerosis, and wherein the protein is IFN beta. 25. A method comprising administering the conjugate of claim 1 to a human or animal in need thereof, wherein the human or animal is in need of treatment for thrombosis, thromboembolism or occlusive arterial diseases, and wherein the protein is APC. 26. A method comprising administering the conjugate of claim 1 to a human or animal in need thereof, wherein the human or animal is in need of treatment for myocardial infarction, thrombosis, thromboembolism or occlusive arterial disease, and wherein the protein is tPA. 27. A method comprising administering the conjugate of claim 1 to a human or animal in need thereof, wherein the human or animal is in need of treatment for emphysema, cystic fibrosis, atopic dermatitis, or bronchitis, and wherein the protein is A1AT. 28. A method comprising administering the conjugate of claim 1 to a human or animal in need thereof, wherein the human or animal is in need of treatment for veno-occlusive disease, disseminated intravascular coagulation, or sepsis, and wherein the protein is AT III. 29. A method comprising administering the conjugate of claim 1 to a human or animal in need thereof, wherein the human or animal is in need of treatment for hemophilia A, and wherein the protein is Factor VIII.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (83)
Cerny Lawrence C. (Utica NY), Acellular resuscitative fluid.
Cuatrecasas ; Pedro ; Parikh ; Indu, Affinity chromatography of vibrio cholerae enterotoxin-ganglioside polysaccharide and the biological effects of ganglio.
Berninger Ronald W. ; Lodge Mark S. ; Tarnowski ; Jr. Stanley Joseph ; Colvin Floyd Warren ; Brinkley John Michael, Aminooxy-containing linker compounds for formation of stably-linked conjugates and methods related thereto.
Stahl Wilhelm (Frankfurt am Main DEX) Ahlers Michael (Mainz DEX) Walch Axel (Frankfurt am Main DEX) Bartnik Eckhart (Wiesbaden DEX) Kretzschmar Gerhard (Eschborn DEX) Grabley Susanne (Koenigstein DEX, Carbohydrate-containing polymers, their preparation and use.
Studier F. William (Stony Brook NY) Davanloo Parichehre (Basel NY CHX) Rosenberg Alan H. (Setauket NY) Moffatt Barbara A. (East Lansing MI) Dunn John J. (Bellport NY), Cloning and expression of the gene for bacteriophage T7 RNA polymerase.
Hedlund Bo E. (New Brighton MN) Hallaway Philip E. (Minneapolis MN) Panter Samuel S. (Minneapolis MN) Eaton John W. (Minneapolis MN), Composition for the stabilization of deferoxamine to chelate free ions in physiological fluid.
Shadle Paula J. (Richmond CA) Koths Kirston E. (El Cerrito CA) Moreland Margaret (Berkeley CA) Katre Nandini (El Cerrito CA), Conjugation of polymer to colony stimulating factor-1.
Sommermeyer Klaus (Rosbach DEX) Cech Franz (Rosbach DEX) Weidler Burghard (Rosbach DEX) Henning Klaus (Usingen DEX), Hydroxylethylstarch (HES) as plasma expander and process for preparing HES.
Dellacherie Edith (Malzeville FRX) Leonard Michle (Neuves-Maisons FRX) Sacco Daniel (Nancy FRX) Vigneron Claude (Nancy FRX), Macromolecular conjugates of hemoglobin, a procedure for their preparation and their uses.
Leonard Michle (Vandoeuvre FRX) Dellacherie Edith (Malzeville FRX) Neel Jean M. L. (Villers-Ls-Nancy FRX) Vigneron Claude (Nancy FRX) Labrude Pierre (Laxou FRX), Macromolecular conjugates of hemoglobin, a procedure for their preparation and their uses.
Davis Frank F. (19 Farmingdale Rd. East Brunswick NJ 08816) Van Es Theodorus (313 Overbrook Rd. Piscataway NJ 08854) Palczuk Nicholas C. (45 W. Franklin St. Bound Brook NJ 08805), Non-immunogenic polypeptides.
Gustavson Linda M. (19809 - 31st St. ; NE. Seattle WA 98155) Anderson David C. (200 Lassen Dr. San Bruno CA 94066) Morgan ; Jr. Alton C. (803 Driftwood Pl. Edmonds WA 98020), Polymeric carriers for non-covalent drug conjugation.
Vanderhoff, John W.; Lu, Cheng Xun; Lee, Clarence C.; Tsai, Chi-Chun, Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtained.
Okada Shigetaka (Nara JPX) Kitahata Sumio (Osaka JPX) Yoshikawa Shigeharu (Okayama JPX) Sugimoto Toshiyuki (Okayama JPX) Sugimoto Kaname (Okayama JPX), Process for the production of branching enzyme, and a method for improving the qualities of food products therewith.
Szablikowski Klaus (Walsrode DEX) Buysch Hans-Josef (Krefeld DEX) Klausener Alexander (Krefeld DEX), Process for the production of polysaccharide carbonates.
Jeannette C. Roberts ; Britta H. Wilmore ; Pamela B. Cassidy ; Pamela K. Dominick ; Megan D. Short, Prodrugs and conjugates of thiol- and selenol- containing compounds and methods of use thereof.
Sommermeyer,Klaus; Zander,Norbert; Frank,Ronald; Conradt,Harald, Starch derivatives, starch active substance conjugates, method for the production thereof and their use as medicaments.
Anthony J. Martinez ; Annapurna Pendri ; Richard B. Greenwald ; Yun H. Choe, Terminally-branched polymeric linkers and polymeric conjugates containing the same.
Lees Andrew ; Mond James J.,ILX, Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts.
Lihme Allan O. F. (Birkerd DKX) Boenisch Thomas (Goleta CA), Water-soluble, polymer-based reagents and conjugates comprising moieties derived from divinyl sulfone.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.